New member in the Ksilink association

Oct 26, 2020 | Short news

We proudly announce that myriamed GmbH is now a member of the Ksilink association. The public private association is aiming to render drug development faster and more efficient, heading towards precision medicine. Together with its partners Ksilink develops and applies patient based disease models for phenotypic drug discovery purposes, and generates novel molecular entities for diseases with a high medical need, such as cardiac disorders. Ksilink is covering the entire preclinical value chain by combining break-through technologies and know-how in patient-based disease modelling, AI based image analysis methodologies, phenotypic drug discovery, pharmacology and medicinal chemistry. This strategic partnership is a key step in myriamed’s efforts to support pharmaceutical companies in the discovery and preclinical testing of novel drug candidates.

To learn more about myriamed’s products please contact us:
https://lnkd.in/em45VNm

To learn more about Ksilink please visit:
http://bit.ly/Ksilink

Share This